ImmunityBio obtains FDA's Expanded Access for Cancer BioShield platform, leading to 18% stock jump.

From Yahoo Finance: 2025-06-24 15:51:00

ImmunityBio Inc. (NASDAQ:IBRX) received Expanded Access authorization from the FDA for its Cancer BioShield platform to treat lymphopenia caused by treatments such as radiotherapy and chemotherapy. This led to an 18% stock jump for IBRX. H.C. Wainwright analyst maintained a Buy rating on IBRX, citing the company’s innovative approach and potential regulatory milestones. ImmunityBio is a clinical-stage immunotherapy company focusing on cancer and infectious diseases.



Read more at Yahoo Finance: ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA